Discussing the 2023 AACR presentation of MCLA-158 (petosemtamab), an IgG1 bispecific antibody targeting EGFR and LGR5, in advanced head and neck squamous cell carcinoma (HNSCC)

Executed on:Jan 24, 2024 3:30 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: UCSD

Chief, Division of Hematology-Oncolog, Associate Director, Translational Science, Moores Cancer Center & co-director of UC San Diego Health's Precision Immunotherapy Clinic at UCSD.
Leads a laboratory that studies novel cancer treatments, including immunotherapy, with a focus on squamous cell carcinomas and cancers of the thyroid, salivary gland, and HPV-related oropharyngeal cancers. 
Recent National Institutes of Health (NIH)-funded work in the study of epidermal growth factor receptor inhibitors in head and neck cancer has contributed to the understanding of the biology of this critical signaling network, integration of these agents into standard of care, and definition of mechanisms to overcome resistance.
Authored more than 170 peer-reviewed papers and has been the principal investigator of multiple clinical trials of new drugs for head and neck cancer and other solid tumors.

Interview Goal

Discuss the AACR presentation with one of the authors

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.